Maureen G Conlan

4PUBLICATIONS
13CO-AUTHORS
Molecular targetsEconometric and statistical methodsOccupational epidemiologyHealth and ecological risk assessment
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (4)

|Aug 29, 2023
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.

Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar

|Sep 11, 2020
A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using 18F-FES PET/CT imaging.

Agnes Jager, Elisabeth G E de Vries, C Willemien Menke-van der Houven van Oordt

|Aug 31, 2020
Correction to: Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.

Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans

|Jul 15, 2020
Pharmacokinetic and Pharmacodynamic Studies of Elacestrant, A Novel Oral Selective Estrogen Receptor Degrader, in Healthy Post-Menopausal Women.

Maureen G Conlan, Erik F J de Vries, Awjm Glaudemans

Pageof 1

Frequent Collaborators

1 joint publications

Glenn J Hanna

1 joint publications

Myung-Ju Ahn

1 joint publications

Jameel Muzaffar

1 joint publications

Bhumsuk Keam